The commonly used chemotherapy regimen for juxtagastric cancer is FOLFIRINOX, i.e., a quadruple chemotherapy regimen composed of calcium folinic acid, oxaliplatin, fluorouracil, and iriconazole; or a chemotherapy regimen based on gemcitabine combined with capecitabine, cisplatin, or paclitaxel can also be used. Pelvic cancer refers to cancer that occurs in the pelvic region of the duodenum, which is a site where the intestinal, pancreatic, and biliary ducts meet, and the anatomical structure is relatively complex. The most common clinical manifestations of jugular cancer are jaundice, fever, epigastric pain, and also gastrointestinal symptoms, enlargement of liver and gallbladder. Currently, the most commonly used treatment is pancreaticoduodenectomy, which is less sensitive to chemotherapy. For patients who cannot tolerate surgery or after surgery after resection of adjuvant therapy can be chemotherapy, according to the guidelines generally selected FOLFIRINOX is generally chosen as the first choice according to the guidelines, with good follow-up results, and is often used as the first-line treatment. Some patients can also choose gemcitabine plus paclitaxel or gemcitabine plus Tegretol as the second-line treatment option. The chemotherapy regimens chosen for different subtypes of pot-bellied cancer are also different. After the patients are clearly diagnosed with pot belly cancer, they should decide the treatment plan comprehensively according to the pathological staging and clinical staging under the guidance of doctors. Patients should inform doctors promptly of any discomfort in the course of chemotherapy to avoid accidents.